TriangleNCT00569582 · OUTCOME
Improvement in Diabetes and/or Glucose Intolerance.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline to Week 24
What was measured
Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance.
Analysis population: Patients with at least 30 days of dosing.
Groups in this outcome
Mifepristone
Mifepristone was administered at doses of 300-1200 mg daily.
| Group | Source count |
|---|---|
| Mifepristone | 25 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Mifepristone | 15 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 15
- denoms
- counts
- group Id
- OG000
- value
- 25
- units
- Participants
- description
- Responder is defined as subject with a decrease greater than or equal to 25% in area under the curve for glucose on 2-hour oral glucose test from baseline to week 24 or last visit, for Cushing's patients with type-2 diabetes mellitus/impaired glucose tolerance.
- groups
- description
- Mifepristone was administered at doses of 300-1200 mg daily.
- id
- OG000
- title
- Mifepristone
- param Type
- NUMBER
- population Description
- Patients with at least 30 days of dosing.
- reporting Status
- POSTED
- time Frame
- Baseline to Week 24
- title
- Improvement in Diabetes and/or Glucose Intolerance.
- type
- PRIMARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice